2013 defied the most doom-laden predictions of being the worst year in a decade in
terms of device maker acquisitions – but only just. With the pure medtech buys
closed in 2013 worth less than half the 2012 total,
the sector made a pretty dismalshowing
, despite two deals worth more than $1bn closing in the second half.
If the deal count is down – 16% on 2012 – the total value of medtech acquisitions
has fallen even further. Just $19.3bn was spent in total last year, less than half 2012’s
total. It should be noted that this analysis excludes acquisition targets with both
pharma and medtech operations; only those companies listed in EvaluateMedTech as
pure medtech have been included. (Más)
martes, 8 de abril de 2014
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario